$0.89
+0.06 (+7.54%)
Open$0.84
Previous Close$0.83
Day High$0.90
Day Low$0.84
52W High$1.94
52W Low$0.71
Volume—
Avg Volume465.5K
Market Cap67.23M
P/E Ratio—
EPS$-0.61
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+570.8% upside
Current
$0.89
$0.89
Target
$6.00
$6.00
$4.29
$6.00 avg
$7.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 29.5K | 9.23M | 9.01M |
| Net Income | -50,002,178 | -678,125 | -522,642 |
| Profit Margin | -155,587.4% | -7.4% | -5.8% |
| EBITDA | -46,205,197 | -963,511 | -904,753 |
| Free Cash Flow | — | -508,030 | -465,093 |
| Rev Growth | — | +6.0% | +24.9% |
| Debt/Equity | 0.02 | 0.23 | 0.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |